DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+24.11%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.85B
AUM Growth
+$2.85B
(+11%)
Cap. Flow
-$74.2M
Cap. Flow
% of AUM
-2.6%
Top 10 Holdings %
Top 10 Hldgs %
41.33%
Holding
76
New
13
Increased
15
Reduced
16
Closed
18
Top Buys
| 1 |
argenx
ARGX
|
$114M |
| 2 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$52.8M |
| 3 |
Sarepta Therapeutics
SRPT
|
$48.2M |
| 4 |
Tourmaline Bio
TRML
|
$47.5M |
| 5 |
ABVX
Abivax
ABVX
|
$46M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$134M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$80.2M |
| 3 |
Immunovant
IMVT
|
$75.7M |
| 4 |
Structure Therapeutics
GPCR
|
$65.8M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $166M | 5.54% | 5,350,000 -650,000 | -11% | -$20.1M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $148M | 4.95% | 4,063,676 +517,241 | +15% | +$18.9M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $143M | 4.78% | 2,000,000 -600,000 | -23% | -$43M |
|
4
Guardant Health
GH
$8.41B
| $135M | 4.52% | 5,000,000 +950,000 | +23% | +$25.7M |
|
|
5
argenx
ARGX
$43.6B
| $114M | 3.81% | +300,000 | New | +$114M |
|
6
Alkermes
ALKS
$4.78B
| $111M | 3.71% | 4,000,000 +200,000 | +5% | +$5.55M |
|
7
Pliant Therapeutics
PLRX
$101M
| $104M | 3.48% | 5,750,000 +250,000 | +5% | +$4.53M |
|
8
Dynavax Technologies
DVAX
$1.19B
| $99.2M | 3.31% | 7,093,214 +336,258 | +5% | +$4.7M |
|
9
Axsome Therapeutics
AXSM
$6.05B
| $79.6M | 2.66% | 1,000,000 -140,745 | -12% | -$11.2M |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $79.1M | 2.64% | 3,631,728 +668,461 | +23% | +$14.6M |
|
|
AUTL
11
Autolus Therapeutics
AUTL
$399M
| $76.4M | 2.55% | 11,869,297 -3,130,703 | -21% | -$20.2M |
|
12
Pacific Biosciences
PACB
$393M
| $68.7M | 2.29% | 7,000,000 +1,000,000 | +17% | +$9.81M |
|
13
Intellia Therapeutics
NTLA
$1.22B
| $68.6M | 2.29% | 2,250,000 +250,000 | +13% | +$7.62M |
|
14
Travere Therapeutics
TVTX
$1.56B
| $66.3M | 2.21% | 7,370,000 | – | – |
|
15
Apogee Therapeutics
APGE
$2.17B
| $64.9M | 2.17% | 2,323,456 -90,917 | -4% | -$2.54M |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $63.4M | 2.12% | 3,187,415 | – | – |
|
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $63.2M | 2.11% | 1,249,068 -1,585,001 | -56% | -$80.2M |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$511M
| $63.1M | 2.11% | 3,490,506 | – | – |
|
19
Geron
GERN
$893M
| $62.4M | 2.08% | 29,583,449 +3,883,449 | +15% | +$8.19M |
|
20
Editas Medicine
EDIT
$231M
| $55.4M | 1.85% | 5,473,086 -1,628,849 | -23% | -$16.5M |
|
|
AMAM
21
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $52.8M | 1.76% | +3,710,412 | New | +$52.8M |
|
|
22
Sarepta Therapeutics
SRPT
$1.78B
| $48.2M | 1.61% | +500,000 | New | +$48.2M |
|
|
23
Tourmaline Bio
TRML
$601M
| $47.5M | 1.59% | +1,815,854 | New | +$47.5M |
|
24
HilleVax
HLVX
$105M
| $46.5M | 1.55% | 2,900,000 | – | – |
|
25
4D Molecular Therapeutics
FDMT
$288M
| $46.3M | 1.55% | 2,284,372 -493,735 | -18% | -$10M |
|